COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Rigosertib for RDEB-SCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03786237
Recruitment Status : Recruiting
First Posted : December 24, 2018
Last Update Posted : March 24, 2020
Information provided by (Responsible Party):
Prof. Johann Bauer, Salzburger Landeskliniken

Brief Summary:

Epidermolysis bullosa (EB) is a heritable skin disease characterized by marked fragility of epithelialized tissue with blistering in skin and mucous membranes following the slightest mechanical trauma. Eighty percent of all patients suffering from recessive dystrophic EB (RDEB), a subtype originating from mutations in the COL7A1 gene, develop squamous cell carcinoma (SCC). In RDEB patients SCC presents early (most patients are in their 20s or 30s) and shows a highly aggressive metastatic course which often leads to premature death at this young age.

In light of scarce data on the efficacy and safety of systemic treatment regimens for advanced SCC, the investigators propose to perform a small, "first in EB " trial of an experimental drug called rigosertib for the treatment of EB cancer. The trial will be conducted in two study centres, in London and Salzburg, and will last approximately 2.5 years with each patient recruited being in the study for 1 year. The drug is a polo-like kinase inhibitor interfering with different molecular pathways that are essential for cancer cell growth. Rigosertib was developed by Onconova Therapeutics and is currently tested in several clinical trials for a number of other cancers including myelodysplastic syndrome (a cancer of the blood). The investigators have identified that rigosertib most selectively kills EB cancer cells in vitro while leaving normal EB skin cells unaffected. This project will evaluate whether rigosertib is capable of inducing an anti-cancer response in EB patients and whether the drug is well-tolerated. Mechanisms of molecular targeting of squamous cancer cells by rigosertib will further be investigated in EB patients, also aiming at the identification of biomarkers that may allow the predictive identification of best responders.

Condition or disease Intervention/treatment Phase
Epidermolysis Bullosa Dystrophica Squamous Cell Carcinoma Drug: Rigosertib Oral Capsules / Rigosertib Oral Liquid Solution / Rigosertib Intravenous Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell Carcinoma
Estimated Study Start Date : May 2020
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : June 2022

Arm Intervention/treatment
Experimental: Treatment Oral Capsules / Oral liquid Solution / Intravenous Drug: Rigosertib Oral Capsules / Rigosertib Oral Liquid Solution / Rigosertib Intravenous

Patients will take Rigosertib either as oral capsules or oral liquid solution or will get intravenous infusions depending on the needs of the patients.

Oral Capsules/ Liquid Solution:

Patients will take oral Rigosertib continuously for a total of three weeks, every four week cycle (three weeks on, one week off drug) for up to 13 cycles. Patients will take 560 mg of oral Rigosertib (ie, 2 capsules of 280 mg or 7,47mL of the concentrate in 30mL water) in the morning and 280 mg of oral Rigosertib (ie, 1 capsule of 280 mg or 3,73mL of the concentrate in 30mL water) in the afternoon, total of 840mg/day.

Intravenous Infusions:

For IV treatment Rigosertib 1800 mg/24 hr is diluted in 0.9% sodium chloride for injection just prior to dosing and is administered as a 72-hr CIV infusion on days 1, 2, and 3 of a 2-week cycle for the first eight 2-week cycles, then on days 1, 2, and 3 of a 4-week cycle thereafter.

Primary Outcome Measures :
  1. Efficacy: Objective Response Rate (ORR) [ Time Frame: 1 year ]
    The primary (efficacy) objective of this trial is to determine the Objective Response Rate (ORR) of therapy with Rigosertib in RDEB patients with locally advanced/metastatic squamous cell carcinoma of the skin using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment up to 52 weeks by CT/MR Scan.

  2. Number of Treatment-related adverse events [ Time Frame: 1 year ]
    Safety will be evaluated for all treated patients, who receive at least one dose of Rigosertib, using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 ( Safety assessments will be based on number of treatment related adverse events per grade.

Secondary Outcome Measures :
  1. Evaluation of quality of life using the "Quality of life in Epidermolysis bullosa questionnaire (QOLEB)" [ Time Frame: 1 year ]
    Assess impact on quality of life using an Epidermolysis bullosa (EB) specific questionnaire developed and published by Murrell et al.2009. Total score is reported (range 0-75; 0 means EB has no affect on ones life, the higher the score the more affect and annoyance/handicap)

  2. Rate of presence or absence of cancer specific biomarkers [ Time Frame: 1 year ]
    Fixed tissue will be assessed using immuno-histochemistry with antibodies raised against phosphorylated AKT (p473 Akt), phosphorylated C-RAF (p-S338 RAF), phosphorylated ERK and cleaved caspase.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. 18-79 years of age;
  2. Diagnosis of unresectable, locally advanced or metastatic SCC confirmed prior to the screening visit.
  3. Failure to respond to RDEB SCC standard of care, such as surgical excision, radiotherapy or conventional cytotoxic chemotherapy with e.g. platin derivates (i.e. cisplatin or carboplatin), 5-fluorouracil, bleomycin, methotrexate, adriamycin, taxanes, gemcitabine or ifosfamide alone or in combination. For recent guidelines on standard of care for RDEB SCC and non EB-SCC please see Mellerio 2016 and Stratigos 2015.
  4. Is not currently receiving any other cancer therapy.
  5. Measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
  6. Patient (or patient's legally authorized representative) must have signed an informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study.

Exclusion Criteria:

  1. Response to standard of care;
  2. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure or unstable angina pectoris;
  3. Active systemic infection not adequately responding to appropriate therapy;
  4. Total bilirubin ≥ 1.5 mg/dL not related to hemolysis or Gilbert's disease;
  5. Alanine transaminase (ALT)/aspartate transaminase (AST) ≥ 2.5 x upper limit of normal (ULN);
  6. Serum creatinine ≥2 .0 mg/dL or eGFR (estimated Glomerular Filtration Rate) <60 mL/min;
  7. White blood cell count ≤ 2000/μl, Neutrophils ≤ 1500/μL, Platelets ≤ 100 x103/μL, Hemoglobin ≤ 7.9 g/dL;
  8. Known active HIV, hepatitis B or hepatitis C, where active is defined as follows: a. HIV or Hepatitis C - presence of viral load b. Hepatitis B - antigen positive;
  9. Uncorrected hyponatremia (defined as serum sodium value of <125 mmol/L);
  10. Female patients of child-bearing potential and male patients with partners of child-bearing potential who are unwilling to follow strict contraception requirements throughout the study, up to and including the 30-day non-treatment follow-up period;
  11. Female subjects: pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS they are willing to use one or more reliable methods of contraception with a Pearl index ≤1. Reliable contraception should be maintained throughout the study. A pregnancy test in urine will be performed at screening in all women of childbearing potential, and repeated before biopsy treatment and at all visits. Any postmenopausal women (physiologic menopause defined as "12 consecutive months of amenorrhea") or women permanently sterilized (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy) will not be required to undergo pregnancy test.
  12. Uncontrolled hypertension;
  13. Patient is currently participating and receiving study therapy or systemic therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
  14. Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.
  15. Patients (or parents in case of paediatric subject) unlikely to comply with the study protocol or unable to understand the nature and scope of the study or the possible benefits or unwanted effects of the study procedures and treatments.
  16. Participation in another clinical trial where investigational drug was received less than 6 months prior to Screening Visit.
  17. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
  18. Known hypersensitivity reaction to any of the components of study treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03786237

Layout table for location contacts
Contact: Manager EB Study Center +43 5 7255 ext 82413
Contact: Elisabeth Mayr, PhD +43 5 7255 ext 80087

Layout table for location information
EB House Austria/Dept. of Dermatology University Hospital Recruiting
Salzburg, Austria, 5020
Contact: Elisabeth Mayr, PhD    +4357255 ext 82413   
Contact: Sophie Kitzmüller, PhD    +4357255 ext 52053   
Sponsors and Collaborators
Prof. Johann Bauer
Layout table for investigator information
Principal Investigator: Johann W Bauer, Prof., MD Department of Dermatology, Paracelsus Medical University, Salzburger Landeskliniken
Layout table for additonal information
Responsible Party: Prof. Johann Bauer, Head of Department of Dermatology, Salzburger Landeskliniken Identifier: NCT03786237    
Other Study ID Numbers: Rigosertib 2.0
First Posted: December 24, 2018    Key Record Dates
Last Update Posted: March 24, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Epidermolysis Bullosa
Epidermolysis Bullosa Dystrophica
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Skin Abnormalities
Congenital Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Vesiculobullous
Collagen Diseases
Connective Tissue Diseases
ON 01910
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action